[Analysis of 1697 cases of childhood malaria treated using intra-rectal Quinimax (QIR) in the Tilaberi health district in Niger].
Management of malaria attacks with vomiting or other complications in rural areas of Africa raises the often insurmountable challenge of transferring patients to medical centers better equipped than health dispensaries providing initial care. In addition intramuscular quinine can lead to complications. Since intrarectal administration of quinine could help to resolve these problems, it should be included in the therapeutic algorithm. The purpose of this study was to validate the safety, acceptability, tolerance, and efficacy of Intra-Rectal Quinimax (QIR) for treatment of children (0 to 10 years) in the rural Tilaberi region of Niger where malaria is endemic. Of the 3012 children enrolled in the study, a total of 1697 benefited from treatment with treatment using QIR. Thirty-five percent of the cases treated involved complicated malaria attacks. Use of QIR caused no problem in terms of safety or acceptability. Duration of surveillance following treatment using QIR in children is particularly important to prevent early evacuation of the product that was observed in 16% of cases. No short-term side effects were observed. Contraindications for QIR were observed in 10% of the patients enrolled in the study. Success and mortality rates were not statistically different after intrarectal and intramuscular administration. A survey to evaluate the skill of care providers was carried out at the onset of the study. The presentation and functionality of the QIR kit was validated by care providers.
Landais
E
E
Actions de solidarité internationale.
Poisson
C
C
Condamine
J L
JL
D000285:Administration, Rectal; D000293:Adolescent; D000962:Antimalarials / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D005240:Feasibility Studies; D005260:Female; D006801:Humans; D007223:Infant; D008137:Longitudinal Studies; D008288:Malaria / Q000188:drug therapy* / Q000453:epidemiology; D008297:Male; D011446:Prospective Studies; D011803:Quinine / Q000627:therapeutic use*; D019035:Rural Health Services; D012424:Rural Population
D000962:Antimalarials; D011803:Quinine